SCOTUS declines Momenta case

The U.S. Supreme Court declined to hear an appeal from Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), rebuffing the company's attempt to stop sales of a competing generic version of anticoagulant enoxaparin. Momenta's patent infringement suit against Amphastar Pharmaceuticals Inc. (Rancho Cucamonga, Calif.) is ongoing in the U.S. District Court for the District of Massachusetts. Momenta was appealing a 2-1 August decision from the U.S. Court of Appeals for the Federal Circuit (CAFC) that vacated a preliminary injunction granted by the district court that would have prevented Amphastar from selling its generic version of the anticoagulant (see BioCentury Extra, June 6). ...